Functional Skills
Business Unit Strategy
Operations Management
Acquisition Target Identification
Business Planning
Commercial Due Diligence
Technology Strategy
Strategy Development
Product Development
PMO Transformation
Growth Strategy
Communications
Genetics
Market Research
Medical Affairs
Sector Experience
Healthcare
Manufacturing
Technology
Life Sciences & Pharma
Chemicals
Languages
English
German
French
5
hours
Avg Response Time
6
jobs
Jobs Completed
169
hours
Total Hours Logged
32
years
Years of Experience
Notable Clients
Celanese
Dow Corning
GSK
Novartis
Pfizer
Big 3 Consulting (MBB)
Top Consulting Firms
Experience
Bilayer Therapeutics, Inc.
Start-Up
President & CEO
New Bob Langer, MIT spin-off, developing first-in-class therapies for metabolic disorder (obesity, diabetes), for constipation and for other diseases of the colon
Collet Consulting LLC
Management Consulting
Principal
Consulting practice serving top institutions in their fields. Projects include business unit strategies; early stage technology commercialization; formation of internal start-ups; clinical development strategies; new business creation; pipeline reviews and quality operations in pharmaceutical manufacturing. Clients include Bayer, Danaher, Dow Corning, GSK, IMRA US, Novartis, Pfizer, Sandoz, Sanofi, Zoetis, universities & start-up companies. Bilingual English & German, passable French
Phrixus Pharmaceuticals, Inc.
Product Management / Strategy
President & CEO
Co-founded this clinical stage specialty pharma company focused on Duchenne muscular dystrophy and heart failure.
Directors: Dr. Leslie Browne (CEO Senesco - SNT), Gerald Brennan (formerly CFO Aastrom, ASTM)
Directors: Dr. Leslie Browne (CEO Senesco - SNT), Gerald Brennan (formerly CFO Aastrom, ASTM)
ProNAi Therapeutics, Inc.
Start-Up
President & CEO
Co-led launch of this early stage DNA Interference (DNAi)-based biopharmaceutical company with focus on oncology therapeutics. Responsible for raising initial $4.5 million, assembling key team, preparing business plan, and executing key product development agreements. Prepared company for next development stage (additional $11 million follow-on funding and IND within next two years). Company went public in July 2015 with a market capitalization of >$800 million (DNAI)
Neural Intervention Technologies, Inc.
Start-Up
President & CEO
Co-founded and led early stage medical device company for the treatment of hemorrhaging stroke, a spin-off company from the University of Michigan, to opening of its first IDE and raised $6.3 million in capital with company. Sale to WL Gore in 2007
Directors: Fred Beyerlein (Rubicon Genomics), Daryl Kipke (University of Michigan)
Directors: Fred Beyerlein (Rubicon Genomics), Daryl Kipke (University of Michigan)
Other
Start-Up
Various
Meditrina Pharmaceuticals, Inc., President & CEO, 2006 - 2014, women's health start-up (endometriosis, uterine fibroids, etc.)
University of Michigan, Mentor-In-Residence, 2009 - 2011, advised senior faculty regarding commercialization
Rubicon Genomics, Inc., President & CEO, 2001 - 2002, life science tools, sold to Takara Bio in January 2017 for $75 million
University of Michigan, Mentor-In-Residence, 2009 - 2011, advised senior faculty regarding commercialization
Rubicon Genomics, Inc., President & CEO, 2001 - 2002, life science tools, sold to Takara Bio in January 2017 for $75 million
Tullis-Dickerson & Co., Inc.
Finance
Partner
In charge of opening and growing new office for the Midwest. As one of 7 investment partners in new $195 million
VC fund responsible for investments from $38 million sub-fund. Focus on early- to mid-stage opportunities in life
sciences, drug discovery, and drug development. Invested in six companies including TransMolecular, Inc., ViaCell,
Inc. (acquired by Perkin Elmer in 2007), Synageva BioPharma, Inc. (formerly Avigenics, Inc.)
VC fund responsible for investments from $38 million sub-fund. Focus on early- to mid-stage opportunities in life
sciences, drug discovery, and drug development. Invested in six companies including TransMolecular, Inc., ViaCell,
Inc. (acquired by Perkin Elmer in 2007), Synageva BioPharma, Inc. (formerly Avigenics, Inc.)
Monsanto Company
Operations
VP Business Development
Started new internal business for the production of therapeutic antibodies, biogenerics/biosimilars in green plants. Wrote key elements of business plan, assisted in generating internal funding of several million $ per year, generated first contracts of ~$2 - $3.5 million for Phase 1 production of first parenteral protein produced in plants. Led business development effort with five contracts executed over 18 months and six more contracts under negotiation
McKinsey & Company
Management Consulting
Engagement Manager
Developed, with top management, high-impact business unit, corporate, and technology strategies for primarily Fortune 100 companies in the pharmaceutical, healthcare, and chemical industries. Started as Associate in Düsseldorf, Germany, left as Engagement Manager from Chicago office.